Indications And Dose
Treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas (monotherapy) ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
PDF page 976
Loading InternPractice…
Drug reference
Treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas (monotherapy) ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
PDF page 976
Active severe infection. risk factors for severe infection
PDF page 976
Active cardiovascular disease. cardiac risk factors. caution in handling—irritant to tissues. concurrent radiotherapy to the mediastinal area. history of cardiovascular disease. previous radiotherapy to the mediastinal area. previous therapy with anthracenediones . previous therapy with anthracyclines
PDF page 976
NICE decisions ▶Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma (February 2014) NICE TA306 Pixantrone (Pixuvri ®) monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma in patients: . who have previously been treated with rituximab, and . who are receiving third- or fourth-line treatment, and . if the manufacturer provides pixantrone with the discount agreed in the patient access scheme. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta306
PDF page 977
→Appendix 1: anthracyclines
PDF page 976
▶Common or very common Alopecia. anaemia. appetite decreased. arrhythmias. asthenia. blood disorder. bundle branch block. cancer progression. cardiac disorder (during or following treatment). chest pain. congestive heart failure. constipation. cough. decreased leucocytes. diarrhoea. drowsiness. dry mouth. dyspnoea. electrolyte imbalance. eye inflammation. fever. gastrointestinal discomfort. haemorrhage. headache. hypotension. increased risk of infection. left ventricular dysfunction. mucositis. nail disorder. nausea. neutropenia. oedema. oral disorders. pain. paraesthesia. proteinuria. secondary malignancy. skin reactions. taste altered. thrombocytopenia. urine discolouration. vascular disorders. vomiting ▶Uncommon Anxiety. arthralgia. arthritis. bone marrow failure. chills. dizziness. dry eye. eosinophilia. hyperbilirubinaemia. hyperuricaemia. local reaction. meningitis. muscle weakness. musculoskeletal stiffness. night sweats. oesophagitis. oliguria. respiratory disorders . rhinorrhoea. septic shock. skin ulcer. sleep disorders. spontaneous penile erection. vertigo. weight decreased
PDF page 976
Ensure effective contraception during and for at least 6 months after treatment in men or women.
PDF page 976
Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 976
Manufacturer advises avoid—no information available.
PDF page 977
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment (no information available).
PDF page 977
No information available— manufacturer advises caution.
PDF page 977
▶Baseline investigations should include a full blood count, assessment of cardiac function measured by left ventricular ejection fraction, and measurement of serum concentrations of total bilirubin and total creatinine. ▶Full blood count and cardiac function should be monitored throughout treatment.
PDF page 977
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ELECTROLYTES: May contain Sodium ▶Pixuvri (Servier Laboratories Ltd) Pixantrone (as Pixantrone dimaleate) 29 mg Pixuvri 29mg powder for concentrate for solution for infusion vials | 1 vial P £553.50 ANTINEOPLASTIC DRUGS › ANTIMETABOLITES
PDF page 977
Photosensitivity Photosensitivity is a theoretical risk and patients should be advised to follow sun protection strategies.
PDF page 977
(consult product literature)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 976